Nebivolol vs Bisoprolol: What to Choose and for Whom

When a doctor decides that a patient needs a beta-blocker, the choice often narrows to a few modern molecules — and nebivolol and bisoprolol are among the most popular. The editorial team examines in which clinical situations each has advantages, what physically active people should know, and why switching one drug for another on your own is a bad idea.

When a beta-blocker is really needed

Beta-blockers have clear indications where their benefit is best proven: heart failure with reduced ejection fraction, prior myocardial infarction, angina, and heart rate control in atrial fibrillation. In these situations a beta-blocker is not 'one of the options' but an important part of therapy.

In hypertension the role of beta-blockers has been debated for years. The ESC/ESH 2018 guidelines recommended them primarily in specific situations — with concomitant ischemic heart disease, heart failure, arrhythmias, and in women planning pregnancy. The ESH 2023 guidelines include them among the main classes but emphasize the importance of concomitant conditions for the choice.

So the first question is not 'nebivolol or bisoprolol' but 'is a beta-blocker needed at all'. For a young person with uncomplicated hypertension, a doctor will more often start with a different class of drug.

Secondary causes of tachycardia and elevated pressure should also be excluded: hyperthyroidism, anemia, excessive caffeine and stimulant use, and use of hormonal drugs. A beta-blocker can 'mask' symptoms without eliminating the cause.

Heart failure and ischemic heart disease

In heart failure with reduced ejection fraction, bisoprolol has the strongest data on reducing mortality — the CIBIS-II trial. That is why in many clinics it is the 'default drug' for such patients of younger and middle age.

Nebivolol has an evidence base in elderly patients (from age 70) based on the SENIORS results. For an elderly patient with heart failure it can be a well-justified choice, especially if a vasodilating effect is also needed.

Regardless of the chosen molecule, in heart failure the dose is increased gradually, from the minimum starting dose, under monitoring of pulse, pressure and well-being. This titration is performed exclusively by a doctor, since a temporary worsening of the condition is possible at the start of treatment.

In stable ischemic heart disease both drugs effectively reduce the frequency of angina attacks by slowing the pulse. The choice here depends on tolerability, kidney and liver function, and concomitant medications.

Hypertension and the metabolic profile

If a beta-blocker is needed for blood pressure control, arguments in favor of nebivolol may be signs of endothelial dysfunction, metabolic syndrome, or complaints of erectile function while on other beta-blockers. NO-mediated vasodilation theoretically softens some of the class's adverse effects, although there is little convincing comparative data.

Bisoprolol may be more appropriate in people taking CYP2D6 inhibitors (some antidepressants), since its concentration is almost independent of these enzymes. Balanced renal and hepatic elimination also makes it predictable in people with moderate impairment of one of these organs.

These arguments are not absolute: in each specific case the doctor weighs them together with other factors — cost, availability, and the patient's experience with previous therapy.

Physically active people and athletes

For people who train regularly, a beta-blocker is a drug with a noticeable effect on well-being. A lower maximum pulse, faster fatigue during aerobic work, and sometimes cold hands and feet. For strength training the effect is usually less noticeable than for running, rowing or cycling.

During therapy, pulse zones calculated by age or by a test without the drug lose their meaning. Intensity is better assessed by the rating of perceived exertion scale or checked with an exercise test performed while already on treatment.

Beta-blockers lower the pulse but do not eliminate the causes of tachycardia or hypertension. If symptoms appeared while using stimulants, 'fat burners' or hormonal drugs, a beta-blocker is not a way to make taking them safer — the cause must be eliminated and a cardiologist examination undergone.

Professional athletes should remember: beta-blockers are on the WADA Prohibited List in certain sports where precision and tremor control matter (in particular shooting and archery). If the drug is needed for medical indications, a therapeutic use exemption may be required.

Safely switching and discontinuing the drug

Beta-blockers cannot be discontinued abruptly. After prolonged use the sensitivity of receptors changes, and sudden cessation can cause tachycardia, a rise in pressure, worsening of angina, and in patients with ischemic heart disease — a heart attack.

Switching from nebivolol to bisoprolol or vice versa is done by a doctor, calculating an equivalent dose and monitoring pulse and pressure. The milligrams of different beta-blockers are not interchangeable.

• Do not change the dose on your own, even if your pressure is 'normal'.
• Tell your doctor about all medications and supplements, in particular antidepressants and antiarrhythmic drugs.
• If your resting pulse is below 50 or you experience dizziness, consult a doctor.
• Warn your doctor about asthma, diabetes, and peripheral circulation problems.

In diabetes, beta-blockers can mask the symptoms of hypoglycemia, in particular palpitations. This applies to both drugs and requires careful glucose monitoring.

Editorial conclusions

Bisoprolol is often chosen for heart failure in middle-aged patients thanks to its strong evidence base and predictable pharmacokinetics.

Nebivolol has advantages in elderly patients with heart failure and may be appropriate when vasodilation matters or there are complaints of side effects from other beta-blockers.

For physically active people, both drugs change the pulse response to exercise, so training should be adapted rather than treatment abandoned on one's own.

More on the pharmacological differences is in the article 'Nebivolol or Bisoprolol: What Is the Difference'. We also recommend the materials 'Telmisartan vs Losartan: What to Choose and for Whom' and a review of the cardiac risks of stimulants.

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9–13.
3. Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215–225.
4. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
5. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874–2071.
6. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54(16):1491–1499.
7. World Anti-Doping Agency. The Prohibited List. Montreal: WADA; щорічне видання.